Novavax, a Maryland-based biotechnology company, announced today that the double-dose vaccine was 96% effective against the original Covid-19 vaccine, but less effective against mutants. ..
The· Company says This vaccine is 96% effective in protecting against mild, moderate and severe illnesses caused by the original Covid-19 virus and is slightly more protective than the Moderna or Pfizer-BioNTech vaccines.
It is 86% effective against the B.1.1.7 virus first discovered in the United Kingdom, but only 55% effective against the B1.351 variant first discovered in South Africa.
None of the Novavax-vaccinated clinical trials, regardless of mutant, were hospitalized for severe Covid-19 or died of the disease.
The company has already signed contracts with countries such as Canada, the United Kingdom, Australia and India, and expects to have a production capacity of 2 billion times by mid-2021.
The Novavax vaccine is different from the mRNA and single-dose Johnson & Johnson vaccines already approved in the United States. This vaccine is composed of nanoparticles that mimic the Covid-19 peplomer. When injected, immune cells in the body react to the vaccine, creating antibodies that block the SARS-Cov-2 virus in the event of a future infection. Nanoparticle vaccines cannot make you sick or give you Covid-19.
What to watch out for
The next step for the company is to apply for an emergency use authorization from the FDA. Novavax said in a recent earnings report that it is in ongoing discussions with the FDA and can apply for an EUA at the earliest. 2nd quarter of 2021..
95.7 million.. This is how many Covid-19 vaccines have been given in the United States so far.
According to Novavax, the vaccine is 96% effective in preventing the original Covid-19 virus.
https:///sites/leahrosenbaum/2021/03/11/novavax-says-vaccine-is-96-effective-at-preventing-original-covid-19-virus/ According to Novavax, the vaccine is 96% effective in preventing the original Covid-19 virus.